Agenix Limited to File for Clinical Trial of Hepatitis B Drug by June

Published: Apr 01, 2013

by Richard Daverman, PhD

March 29, 2013 -- The Australia-headquartered biopharma Agenix now expects to file a China clinical trial application for its hepatitis B drug candidate, AGX-1009, with the SFDA by June of this year. Agenix hopes to begin a Phase I trial of AGX-1009 in the first half of 2014. Agenix will position the drug as a low-cost, once-daily treatment for hepatitis B patients who have developed resistance to other treatments. More details....

Stock Symbol: (ASX: AGX)

Back to news